Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Complexity in unclassified auto-inflammatory disease: a case report illustrating the potential for disease arising from the allelic burden of multiple variants

Fig. 1

Timeline of canakinumab treatment, serum amyloid (SAA) concentration, and major disease flares. Bars show SAA concentrations (y-axis, ng/ml × 103, performed at Dynacare Laboratories, Canada; * exceeded upper limit of detection). Grey shading shows the start and end of periods (x-axis, month/year) of canakinumab treatment with doses (mg/kg) and duration (days) annotated above. Stars represent major disease flares lasting for more than 5 days and characterized by increased temperature, skin changes, abdominal pain and/or headaches

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096